Inhibition of tumor metastasis
AssigneeGenentech, Inc.
InventorsYan Wu, Wei-Ching Liang, Ryan Jefferson Watts, Anil Durgadas
Life of this patent
Estimating the term…
Abstract
The invention provides Nrp2 antagonists, such as anti-Nrp2 antibodies, and their use in the prevention and treatment of tumor metastasis.
Claims38
A method for inhibiting lymphatic endothelial cell migration, comprising administering to a mammalian subject in need an effective amount of an anti-neuropilin2B (anti-Nrp2B) antibody, or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment:
- i) comprises complementarity determining region light chain (CDRL)1, CDRL2, and CDRL3 sequences and complementarity determining region heavy chain (CDRH)1, CDRH2, CDRH3 sequences of an antibody selected from the group consisting of YW68.4.2 and YW68.4.2.36;
- ii) is a variant of the antibody of (i) having one to five alterations in the framework regions, wherein the light chain framework regions comprise residues 1-23, 35-49, 57-88 and 98-107 or 1-25, 33-49, 53-90 and 97-107 and the heavy chain framework regions comprise residues 1-30, 36-49, 66-94 and 103-113 or 1-25, 33-52, 56-95 and 102-113;
- or
- iii) is an affinity matured variant of the antibody of (i).
A method for inhibiting tumoral lymphangiogenesis, comprising administering to a tumor-bearing mammalian subject an effective amount of an anti-neuropilin2B (anti-Nrp2B) antibody, or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment:
- i) comprises complementarity determining region light chain (CDRL)1, CDRL2, and CDRL3 sequences and complementarity determining region heavy chain (CDRH)1, CDRH2, CDRH3 sequences of an antibody selected from the group consisting of YW68.4.2 and YW68.4.2.36;
- ii) is a variant of the antibody of (i) having one to five alterations in the framework regions, wherein the light chain framework regions comprise residues 1-23, 35-49, 57-88 and 98-107 or 1-25, 33-49, 53-90 and 97-107 and the heavy chain framework regions comprise residues 1-30, 36-49, 66-94 and 103-113 or 1-25, 33-52, 56-95 and 102-113;
- or
- iii) is an affinity matured variant of the antibody of (i).
A method for treating tumor metastasis, comprising administering to a tumor-bearing mammalian subject an effective amount of an anti-neuropilin2B (anti-Nrp2B) antibody, or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment:
- i) comprises complementarity determining region light chain (CDRL)1, CDRL2, and CDRL3 sequences and complementarity determining region heavy chain (CDRH)1, CDRH2, CDRH3 sequences of an antibody selected from the group consisting of YW68.4.2 and YW68.4.2.36;
- ii) is a variant of the antibody of (i) having one to five alterations in the framework regions, wherein the light chain framework regions comprise residues 1-23, 35-49, 57-88 and 98-107 or 1-25, 33-49, 53-90 and 97-107 and the heavy chain framework regions comprise residues 1-30, 36-49, 66-94 and 103-113 or 1-25, 33-52, 56-95 and 102-113;
- or
- iii) is an affinity matured variant of the antibody of (i).
Dependencies are inferred from the claim text.